• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Tagged: reports

  • Chronic Lymphocytic Leukemia After Fludarabine Failure
    • in News · Oncology
    • — 26 Feb, 2008

    Chronic Lymphocytic Leukemia After Fludarabine Failure

    John Gribben
    John Gribben

    Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
    JOHN GRIBBEN, Bartholemews Hospital, London
    New promise for treating chronic lymphocytic leukemia is arising from combining antibody therapies rituximab and alemtuzumab with new drugs such as
    …
    Read more
    • in Oncology
    • — 11 Dec, 2007

    Live Report from ASH:
    Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

    Anton Hagenbeek
    Anton Hagenbeek

    ANTON HAGENBEEK, University Medical Centre Utrecht
    For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH
    …
    Read more
    • in Oncology
    • — 11 Dec, 2007

    Live Report from ASH:
    Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?

    Christian Geisler
    Christian Geisler

    CHRISTIAN GEISLER, Rigshospitalet, Copenhagen
    Mantle cell lymphoma, which was previously considered incurable, has apparently been cured in some patients on a phase II study. Derek Thorne got the details on the study – which featured an intensive immunochemotherapy
    …
    Read more
    • in Oncology
    • — 10 Dec, 2007

    Live Report from ASH:
    Oblimersen Extends Survival in Chronic Lymphocytic Leukemia

    Susan O’Brien
    Susan O’Brien

    SUSAN O’BRIEN, MD Anderson Cancer Center, Houston
    For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan O’Brien presented data from this phase III trial to the American Society of Hematology
    …
    Read more
    • in Oncology
    • — 10 Dec, 2007

    Live Report from ASH:
    Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML

    Richard Stone
    Richard Stone

    RICHARD STONE, Dana-Farber Cancer Institute, Boston
    GEORGE CANELLOS, Dana-Farber Cancer Institute

    New data shows that dasatinib is giving durable responses in patients with chronic phase chronic myeloid leukemia who have failed, or who cannot tolerate imatinib. So where
    …
    Read more
    Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes
    • in Oncology
    • — 10 Dec, 2007

    Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes

    Pierre Fenaux
    Pierre Fenaux

    PIERRE FENAUX, Paris 13 University
    Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University
    …
    Read more
    • in Oncology
    • — 10 Dec, 2007

    Live Report from ASH:
    Interleukin-2 For Acute Myeloid Leukemia In First Remission?

    Jonathan Kolitz
    Jonathan Kolitz

    JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY
    GEORGE CANELLOS, Dana-Farber Cancer Institute

    For patients with acute myeloid leukemia in first remission, new data suggests that there may be a benefit from interleukin-2. Derek Thorne got the interim
    …
    Read more
    TRITON-TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention?
    • in Cardiovascular
    • — 5 Nov, 2007

    TRITON-TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention?

    Gordon Tomaselli
    Gordon Tomaselli
    Daniel Jones
    Daniel Jones

    REFERENCE: Late Breaking Clinical Trials 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
    GORDON TOMASELLI, Johns Hopkins University, Baltimore
    COMMENT: DANIEL JONES, President, American Heart Association, University of Mississippi, Jackson

    A potential new
    …
    Read more
  • BORIS: A. baumanni Highly Resistant β-Lactamase and Varying Susceptibility Patterns
    • in General Medicine
    • — 21 Sep, 2007

    BORIS: A. baumanni Highly Resistant β-Lactamase and Varying Susceptibility Patterns

    Jennifer Lavrrar, Jane Hata, Jeanette Block
    Jennifer Lavrrar, Jane Hata, Jeanette Block

    REFERENCE: Slide Session C2-1360, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
    JANE HATA, bioMéríeux Inc, Durham
    Reports from the BORIS study call for ongoing surveillance of multi-drug resistant Acinetobacter
    …
    Read more
    KRAS Mutation: Powerful Molecular Predictor of Cetuximab Response in Patients With Metastatic Colorectal Cancer
    • in Oncology
    • — 31 Aug, 2007

    KRAS Mutation: Powerful Molecular Predictor of Cetuximab Response in Patients With Metastatic Colorectal Cancer

    Pierre Laurent-Puig
    Pierre Laurent-Puig
    Bill Hait
    Bill Hait

    REFERENCE: ABSTRACT: 5671, American Association for Cancer Research, April 14-18, 2007, Los Angeles
    PIERRE LAURENT-PUIG, Hôpital Européen Georges Pompidou, Paris
    COMMENT: BILL HAIT, Johnson & Johnson, Raritan, NJ

    The presence of the KRAS mutation in tumor
    …
    Read more
  • ASCO Annual Meeting Daily News Podcasts – June 5th, 2007
    • in ASCO · Oncology
    • — 5 Jun, 2007

    ASCO Annual Meeting Daily News Podcasts – June 5th, 2007

    Aimery de Gramont
    Aimery de Gramont
    Robert Mayer
    Robert Mayer

    MOSAIC Study Six Year Results: Adjuvant Oxaliplatin Adds Survival Advantage for Patients with Stage III Colorectal Cancer

    REFERENCE: 4007, ASCO Annual Meeting Chicago June 1-5, 2007
    AIMERY DE GRAMONT, St Antoine Hospital, Paris
    COMMENT: ROBERT
    …
    Read more
    ASCO Annual Meeting Daily News Podcasts – June 4th, 2007
    • in ASCO · Oncology
    • — 5 Jun, 2007

    ASCO Annual Meeting Daily News Podcasts – June 4th, 2007

    Josep Llovet
    Josep Llovet
    Robert Mayer
    Robert Mayer

    Sorafenib The ‘New Standard’ for Advanced Liver Cancer

    REFERENCE: ABSTRACT 5 (Plenary Session), ASCO Annual Meeting Chicago June 1-5, 2007
    JOSEP LLOVET, IDIBAPS Hospital Clinic, Barcelona, and Mount Sinai School of Medicine, New York
    COMMENT: ROBERT
    …
    Read more
  • Next Page »
  • Sign up for AudioMedica.com news

    * = required field
    Speciality




  • Home
  • Tagged: reports

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.